- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07626359
Randomized Non-inferiority Within-Patient Trial of Density Gradient Processing of Sequential Ejaculates Versus Centrifugation-free Sperm Separation Device for ICSI in Men With Elevated Sperm DNA Fragmentation. (SE)
Elevated SDF can adversely impact fertilization, embryo development, and pregnancy outcomes in IVF-ICSI cycles. Two pragmatic strategies aim to reduce SDF on the day of ICSI: (i) obtaining a second ejaculate shortly after the first to reduce oxidative damage and transit time; and (ii) selecting sperm via centrifugation-free sperm separation device, which enriches for motile sperm with intact DNA. There are limited direct comparisons between these strategies; this study addresses that gap.
Studieoversikt
Status
Forhold
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Shashank Sanagoudar, MS
- Telefonnummer: 91-8050406053
- E-post: drsanagoudar@gmail.com
Studer Kontakt Backup
- Navn: Sandro Esteves, PhD
- E-post: s.esteves@androfert.com.br
Studiesteder
-
-
Bihar
-
Patna, Bihar, India, 800014
- Recruitment
-
-
Karnataka
-
Bangalore, Karnataka, India, 560078
- Indira IVF Hospital Limited
-
Underetterforsker:
- Shyam Gupta, MD
-
Ta kontakt med:
- Shyam Gupta, MD
- E-post: centerhead.bangalore@indiraivf.in
-
-
Maharashtra
-
Bhāndup, Maharashtra, India
- Recruitment
-
Pune, Maharashtra, India
- Recruitment
-
-
National Capital Territory of Delhi
-
Delhi, National Capital Territory of Delhi, India
- Recruitment
-
-
Rajasthan
-
Jaipur, Rajasthan, India
- Recruitment
-
Udaipur, Rajasthan, India, 313001
- LAB
-
Ta kontakt med:
- Vipin Chandra, DGO
- E-post: drvipinchandra@indiraivf.in
-
Ta kontakt med:
- Shashank Sannagoudar, MS
- Telefonnummer: 8050406053
- E-post: drsanagoudar@gmail.com
-
-
Uttar Pradesh
-
Allahābād, Uttar Pradesh, India
- Recruitment
-
Lucknow, Uttar Pradesh, India
- Recruitment
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
• Elevated SDF defined as DFI >20 %measured by the sperm chromatin dispersion (SCD) test performed in a participating center's andrology laboratory, using a harmonized protocol under standardized conditions after 2-3 days of ejaculatory abstinence, and within 90 days (≤3 months) prior to enrollment.
- Male partners 21-45 years;
- Female partners 21-35 years.
- Undergoing IVF/ICSI.
- No known genetic or chromosomal abnormalities.
- Minimum 4 MII oocyte patients shall be included
Exclusion Criteria:
- Azoospermia or severe oligoasthenozoospermia (<1 million motile sperm/mL).
- Significant systemic disease (e.g., uncontrolled diabetes, malignancy).
- History of a prior ICSI cycle with no embryo development.
- Relevant female factors: untreated adnexal pathology ,a history of a thin endometrium (<7 mm) following endometrium preparation for embryo transfer
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: First Ejaculate
Processed using a centrifugation-free sperm sorting device |
Processed using density gradient centrifugation |
|
Eksperimentell: Second Ejaculate
The second ejaculate will be processed with two-layer density gradient centrifugation followed by standard washing. |
The second ejaculate will be processed with two-layer density gradient centrifugation followed by standard washing. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Ongoing Pregnancy Rate
Tidsramme: 12 weeks of gestation
|
Ongoing pregnancy rate |
12 weeks of gestation
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Sperm motility and morphology after sperm sorting or second ejaculate collection.
Tidsramme: At the day of ICSI
|
Sperm motility and morphology after sperm sorting or second ejaculate collection. |
At the day of ICSI
|
|
Blastocyst rate
Tidsramme: Day 5&6 after ICSI
|
Blastocyst rate |
Day 5&6 after ICSI
|
|
Good Blastocyst rate
Tidsramme: Day 5&6 after ICSI
|
Total number of good blast |
Day 5&6 after ICSI
|
|
Biochemical Pregnancy Rate
Tidsramme: 2 weeks after embryo transfer
|
Biochemical Pregnancy Rate |
2 weeks after embryo transfer
|
|
Implantation Rate
Tidsramme: 4-6 weeks after embryo transfer
|
An embryo implantation rate is the percentage of transferred embryos that successfully attach to the uterine lining and develop into a clinical pregnancy |
4-6 weeks after embryo transfer
|
|
Clinical Pregnancy Rate
Tidsramme: 4-6 weeks after embryo transfer
|
measures the percentage of fertility treatment cycles (like IVF) that result in a pregnancy confirmed by an ultrasound showing a gestational sac or fetal heartbeat |
4-6 weeks after embryo transfer
|
|
First trimester Miscarriage Rate
Tidsramme: Till 12 weeks after embryo transfer
|
Miscarriages are very common, occurring in about 10% to 20% of all known pregnancies. |
Till 12 weeks after embryo transfer
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Vipin Chandra, DGO, Indira IVF Hospital Limited
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Humaidan P, Haahr T, Povlsen BB, Kofod L, Laursen RJ, Alsbjerg B, Elbaek HO, Esteves SC. The combined effect of lifestyle intervention and antioxidant therapy on sperm DNA fragmentation and seminal oxidative stress in IVF patients: a pilot study. Int Braz J Urol. 2022 Jan-Feb;48(1):131-156. doi: 10.1590/S1677-5538.IBJU.2021.0604.
- https://www.sciencedirect.com/science/article/pii/S0015028215018749
- Chandra V, Sanagoudar S, Shinde J, Shah N, Suwalka I, Esteves SC. Randomized non-inferiority within-patient trial of density gradient processing of sequential ejaculates versus centrifugation-free sperm separation device for ICSI in men with elevated sperm DNA fragmentation- study protocol. Front Urol. 2026 Sep 28;6:1913330. doi: 10.3389/fruro.2026.1913330. eCollection 2026.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- IIHL-UDR/P/007_2025
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Data will be shared on request
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .